ONTX - オンコノバ・セラピュ―ティクス (Onconova Therapeutics Inc.)

ONTXのニュース

   Onconova Therapeutics Highlights Corporate Progress and Reports Second Quarter 2020 Financial Results  2020/08/12 20:05:00 GlobeNewswire
INSPIRE Phase 3 trial survival events reachedTopline data anticipated Q3-2020 Conference call and webcast scheduled today, August 12, at 4:30 p.m. ET …
   Onconova Therapeutics to Provide Corporate Update and Second Quarter 2020 Earnings on August 12, 2020  2020/08/07 12:00:00 GlobeNewswire
Company to host conference call and webcast at 4:30 p.m. Eastern Time on Wednesday, August 12
   Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis  2020/07/29 17:30:00 GlobeNewswire
Topline INSPIRE Results are Expected by the End of the Third Quarter of 2020
   Onconova files for NIH funding for studies of rigosertib in COVID-19 (NASDAQ:ONTX)  2020/07/27 12:25:37 Seeking Alpha
Onconova Therapeutics (NASDAQ:ONTX) has submitted an application to the National Institute of Allergy and Infectious Disease (NIAID) aimed at obtaining fun
   Onconova Therapeutics Submits Application for Rigosertib to Participate in Federally Funded Human Studies in COVID-19 Disease  2020/07/27 12:00:00 Yahoo Finance
Preclinical experiments with rigosertib in cellular models demonstrate marked inhibition of SARS-CoV-2 replicationNEWTOWN, Pa., July 27, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products
   Onconova Therapeutics to Provide Corporate Update and Second Quarter 2020 Earnings on August 12, 2020  2020/08/07 12:00:00 GlobeNewswire
Company to host conference call and webcast at 4:30 p.m. Eastern Time on Wednesday, August 12
   Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis  2020/07/29 17:30:00 GlobeNewswire
Topline INSPIRE Results are Expected by the End of the Third Quarter of 2020
   Onconova files for NIH funding for studies of rigosertib in COVID-19 (NASDAQ:ONTX)  2020/07/27 12:25:37 Seeking Alpha
Onconova Therapeutics (NASDAQ:ONTX) has submitted an application to the National Institute of Allergy and Infectious Disease (NIAID) aimed at obtaining fun
   Onconova Therapeutics Submits Application for Rigosertib to Participate in Federally Funded Human Studies in COVID-19 Disease  2020/07/27 12:00:00 Yahoo Finance
Preclinical experiments with rigosertib in cellular models demonstrate marked inhibition of SARS-CoV-2 replicationNEWTOWN, Pa., July 27, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products
   Onconova Therapeutics Announces Participation in Noble Capital Markets Investor Webinar  2020/06/23 12:00:00 GlobeNewswire
NEWTOWN, Pa., June 23, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on…
   Onconova Therapeutics (ONTX): FY2019 Earnings Snapshot  2020/03/25 12:28:03 news.alphastreet.com
— Onconova Therapeutics (NASDAQ: ONTX) reported FY2019 net loss of $1.49 per share, vs. $4.99 per share last year. — Net loss was $21.5 million compared to $20.4 million last year. — Research and development expenses were $15.5 million versus $16.9 million for 2018. — Cash and cash equivalents as of December 31, 2019, totaled […]
   Onconova (ONTX) to Report Q4 Earnings: What's in Store?  2020/03/02 14:54:00 Zacks Investment Research
Onconova (ONTX) will focus on the updates on lead candidate, Rigosertib, when it reports fourth-quarter 2019 results.
   Onconova regains rigosertib rights in China; shares up 17% premarket  2020/01/23 14:17:57 Seeking Alpha
Onconova Therapeutics (NASDAQ:ONTX) is up 17% premarket on robust volume in reaction to its announcement that it has regained the rights to rigosertib in G
   Onconova Therapeutics, Inc. Announces $10 Million Registered Direct Offering Priced At-The-Market  2019/12/31 16:30:00 GlobeNewswire
NEWTOWN, Pa., Dec. 31, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage…
   Onconova Therapeutics, Inc. Announces Closing of $11.0 Million Public Offering  2019/11/25 14:26:03 GlobeNewswire
Offering led by healthcare dedicated funds, including Knight Therapeutics Inc., along with officers and directors of Onconova

calendar